Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Press release: Uppsala, Sweden, November 17, 2023. Dicot AB (publ) today announces that the exercise of warrants series TO5 was approximately 85.4 percent of the outstanding number. Through the exercise of 192,414,488 warrants, 192,414,488 shares were subscribed for at a subscription price of SEK 0.086 per share. Dicot is thus provided with approximately 16.5 MSEK before issue costs. No subscription guarantees had been procured prior to the exercise.
"I would like to say a big thank you to everyone who subscribed and therby showed their confidence in Dicot and the exiting time we have ahead of us. A subscription rate of over 85% is a very good outcome in the current market climate. I would also like to thank our advisors for their support; Corpura Fondkommission and Advokatfirman Lindahl", comments Elin Trampe, CEO of Dicot.
Through the exercise of the warrants, the number of shares in Dicot increases by 192,414,488 shares, from 625,147,346 shares to 817,561,834. The share capital increases by 1,346,901.42 SEK, from 4,376,031.42 SEK to 5,722,932.84 SEK. For existing shareholders who have not exercised warrants of series TO5, the dilution amounts to approximately 23,5 percent.
Through the exercise of TO5, Dicot will receive approximately 16.5 MSEK before issue costs. There are no costs for guarantees as such agreements have not been concluded.
Exercised warrants TO5 have now been replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office. Conversion of interim shares to ordinary shares is expected to take place around November 28, 2023.
In January 2023, Dicot carried out a rights issue of units, consisting of four new shares, three warrants of series TO4, and three warrants of series TO5. One TO4 entitled the holder to subscribe for one new share in Dicot June 1-15, 2023 and one TO5 to subscribe for one new share November 1-15, 2023.
Complete terms of the warrants are available at Dicot's homepage www.dicot.se.
Advisors
Corpura Fondkommission AB (www.corpura.se) acts as financial advisor and Advokatfirman Lindahl KB as legal adviser to the Company in connection to the exercise of warrants. Hagberg & Aneborn Fondkommission AB acts as issuing agent.
For further information, please contact
Elin Trampe, CEO Björn Petersson, CFO
Phone: +46 72 502 1010 Phone: +46 76 109 0000
E-mail: elin.trampe@dicot.se E-mail: bjorn.petersson@dicot.se
About Dicot
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 4,400 shareholders. For more information, please visit www.dicot.se.
This disclosure contains information that Dicot AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-11-2023 10:58 CET.